Category Archives: oud

Imperva Topples On Mixed Guidance But Clobbers Q4 Expectations

Cybersecurity firm Imperva ( IMPV ) topped analysts’ Q4 views, but its strangled current-quarter and 2016 guidance sent its shares to nose-diving to a 10-month low on Wall Street Thursday. Imperva stock was down 14% in midday trading on the stock market today , near 42.50, earlier falling as low as 41.81, after the company’s late Wednesday earnings report. At least four analysts cut their price targets on Imperva stock. For Q4, Imperva reported 20 cents earnings per share ex items on $72.7 million in sales, topping analysts projections for 15 cents and $68.1 million, and topping the company’s earlier view for 10-16 cents and $66 million to $68 million. Sales rose 41% year over year, and EPS minus items swung from a four-cent loss in the year-earlier quarter. Imperva wrapped up the year with $234.3 million in sales, up 43%, and 11 cents EPS ex items, swinging from a 74-cent loss in 2014. Both measures beat Wall Street expectations and the company’s forecast three months ago. Imperva’s Q1 Losses Expected To Deepen Current-quarter and 2016 guidance was a mixed bag. For Q1, Imperva sees $58 million to $60 million in sales and a 26-32 loss per share ex items. The sales view roughly met the consensus for $59.8 million, but Wall Street was expecting losses of just 11 cents a share ex items. On a year-over-year basis, Q1 sales would be up 32% at the midpoint of guidance, but losses would stagnate or deepen from 26 cents in the year-earlier quarter. Imperva guided 2016 sales at $302 million to $307 million, which would be up 30% at the midpoint. In September, Imperva saw 25% growth in 2016. But the EPS ex items view for 20 cents missed the consensus model for 30 cents, Summit Research analyst Srini Nandury wrote in a research report. Nandury and Piper Jaffray analyst Andrew Nowinski separately blamed the guidance flop on Imperva’s plan to invest more heavily in sales and marketing as well as research and development to gain market share. Both expect that Imperva’s guidance was conservative. Major breaches drove massive growth in earlier quarters and years, Nowinski wrote in a research report. But that “panic buying” has slowed, he says. “It is becoming clear that in the absence of ‘panic buying,’ the security space can still deliver strong top-line growth, but that growth will come at a higher-than-expected cost,” he wrote. Nowinski maintained his overweight rating on Imperva stock but slashed his price target to 54 from 84. Nandury dropped his price target to 70 from 80 but reiterated a buy rating on Imperva stock. Subscription Sales Drive Top Line Subscription revenue of $14.9 million, up 105%, drove Imperva’s top line, Nowinski wrote. The number of $100,000-plus deals grew 15.4% vs. the year-earlier quarter, “and the company did more seven-figure deals than in the entire history of the company.” William Blair analyst Jonathan Ho suggested long-term investors take advantage of Imperva’s stock weakness. Imperva stock is down 33% in 2016. “The fundamentals appear strong,” Ho wrote in a report. “However, we concede there will likely be some continued short-term volatility for security stocks in general due to challenging market conditions.” IBD’s 26-company Computer Software-Security industry group was down 2% midday Thursday and is down 20% for the year, earlier in the day touching a 16-month low.  Palo Alto Networks ( PANW ) and CyberArk Software ( CYBR ) lead the group with Composite Ratings of 81 and 80, respectively, out of a best-possible 99. Imperva stock has a CR of 47. Image provided by Shutterstock .

Abiomed, Boston Scientific Move Opposite Ways On Quarterly Reports

Medical device maker Abiomed ( ABMD ) popped in early trading after it beat quarterly estimates and raised guidance Thursday, while its larger counterpart Boston Scientific ( BSX ) was falling after a more mixed report. Abiomed’s earnings for its fiscal Q3 ended Dec. 31 totaled 23 cents a share, down 23% from the year-earlier quarter but well ahead of analysts’ consensus of 15 cents as reported by Thomson Reuters. Sales rose 38% to $85.8 million, about $5 million above consensus. Abiomed raised its revenue guidance for the full fiscal 2016 to $326 million, up from a previous range of $305 million to $315 million. It said that sales in the current quarter should be $90 million, above Wall Street’s estimate of $85.1 million and up from $62.6 million in last year’s fourth quarter. The company didn’t guide earnings, but it did say that gross profit margin should be higher than its previous guidance of 15% to 17%. Abiomed stock was up 5% in morning trading on the stock market today , near 89. The news wasn’t a total surprise, since Abiomed issued preliminary Q3 sales last month that matched the current report. Leerink analyst Danielle Antalffy wrote that the EPS and guidance numbers brought further upside, supporting strong uptake of Abiomed’s Impella heart pump. “In the U.S., Abiomed clearly continues to drive what we believe is sustainable adoption momentum that should continue to ramp with the recent Impella 2.5 PMA (premarket approval), as the company can more aggressively market to physicians than before,” Antalffy wrote in a research note. “This is further supplemented by the Impella RP and upcoming late-calendar-year 2016 Japan regulatory and reimbursement approval.” Boston Scientific Revenue Falls Short Boston Scientific stock was down 4% Thursday morning, near 17, after the company reported Q4 sales of $1.98 billion, up 5% from the prior year’s Q4 but about $16 million below consensus. Profit rose 18% to 26 cents a share, a penny over the Street. Boston Scientific said that sales in the current quarter should be $1.89 billion to $1.94 billion, somewhat on the low side of analysts’ $1.93 billion consensus, though up from $1.77 billion last year. It said earnings will be 23 to 25 cents a share, in line with consensus and up from 21 cents last year. For the year, the company’s sales guidance of $7.9 billion to $8.1 billion bracketed consensus, while EPS was on the high side at $1.03 to $1.07. “Gross margins (in Q4) came in slightly above our expectations, but operating expenses came in well above our estimate driven by higher sales, general and administrative and R&D expenses, that were offset by tax (which we estimate contributed 1 to 2 cents),” Evercore ISI analyst Vijay Kumar wrote in an email to clients. “Overall, in the context of a tough health care tape and concerns over slowdown in emerging markets and ICD (implantable cardioverter defibrillator) share losses, we view today’s print and guidance as solid.” Image provided by Shutterstock .

Apple Supplier NXP Semiconductors Earnings Beat Amid ‘Challenges’

Apple ( AAPL ) supplier NXP Semiconductors ( NXPI ) reported much-better-than-expected fourth quarter earnings and revenue late Wednesday, despite some “challenges.” Fellow iPhone chipmaker Qorvo ( QRVO ) on tap after the market close Thursday. NXP Semiconductors earned $1.25 a share excludng various items, down 7% vs. a year earlier but easily exceeding Wall Street estimates for $1.07. Revenue climbed 4.5% to $1.61 billion. Analysts had expected a 16% drop to $1.29 billion. The fourth-quarter results include one month of contribution from newly acquired Freescale Semiconductor. The Freescale deal is aimed at making NXP an automotive chip powerhouse. Automotive-related sales rose 45% to $422 million. The deal also halves its Apple iPhone exposure. For the current Q1, NXP expects revenue of $2.15 billion to $2.27 billion with non-GAAP EPS of $1.05-$1.15. Analysts expect Q1 EPS of $1.09. Revenue also was in line. “Looking forward, our task is to continue to outgrow the market despite the uncertain environment,” said CEO Richard Clemmer. NXP stock rose 6.2% in morning trading On Wednesday, shares closed down 3.1% on the  stock market , near 52-week lows set last month. Apple rose 0.6% intraday. On Wednesdsay, its shares rallied 2%, as Apple regained its market cap crown from Alphabet ( GOOGL ) after Alphabet took the lead on Tuesday.  (Alphabet lost 4% Wednesday.) Late Thursday, Qorvo should report a 16% sales decline to $620.3 million, with non-GAAP EPS down 37% to 94 cents. Qorvo slashed its revenue forecast in December. Goldman Sachs downgraded Qorvo Wednesday, saying it’s losing out to rival radio frequency chipmaker  Skyworks Solutions ( SWKS ), yet another Apple supplier. Qorvo stock rose 3.4% after losing 0.2% Wednesday. Skyworks Solutions dipped 0.4% intraday after falling 0.4% on Wednesday.